Device Trial Radar · NCT06754046
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
476
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- University Hospitals Cleveland Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kaiser Permanente; Duke University; Patient-Centered Outcomes Research Institute; University of California, San Diego; University of California, Irvine; MetroHealth Medical Center; Ohio State University; Northwestern University; University of New Mexico; Medstar Health Research Institute; University of Michigan
- First posted
- Dec 31, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if retropubic midurethral sling (RP-MUS) or bulkamide injection (PAHG) at the time of pelvic organ prolapse repair is better from the patient's perspective. The main questions it aims to answer are: What is the average difference in the urogenital distress inventory (UDI) long form score 24 months after surgery for each procedure? Which procedure has the fewest complications and lowest short- and long-term morbidity profile? Participants will: Be blinded and randomized to one of two procedures for the duration of the study, 24 months. Complete 6 total visits for the clinical trial including validated questionnaires. Few participants will be selected to complete a qualitative interview at 3 timepoints over 24 month duration of the study.
Conditions
- Stress Urinary Incontinence
- Vaginal Prolapse
Interventions
RP-MUSDevice
a standard urethral sling placement for treatment of stress urinary incontinence
PAHGProcedure
A standard 2 mL dose injection of bulkamid (order and number will be at the discretion of the surgeon) will be given. Patients undergoing PAHG will be given sham incisions consisting of superficial suprapubic epidermal scratches with a needle and fibrin glue at expected sling exit sites.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bothersome stress urinary incontinence symptoms as measured by urogenital distress inventory long form (UDI)Time frame: 24 months postoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.